Massive Half-Million patient study probes safety of popular eye drug

This study looked back at the medical records of 550,000 patients who received aflibercept (Eylea) injections for common eye diseases like macular degeneration and diabetic eye swelling. The goal was to measure how often a serious eye inflammation called retinal vasculitis occurred after the injections. Researchers used a large national eye disease registry to find and confirm these cases, aiming to better understand the drug's safety profile in real-world use.